Harry Bull

Researching #AML ⏭ #HSCT #bmtsm #leusm #endotheliitis

[Harry Bull @hottibull]

Endothelial syndrome vs VOD/SOS.

More work to understand, assess, & treat post-allo #HSCT related endothelial damage

Need comprehensive classificatn & frontline & prophylactic strategies

https://t.co/RAr8KS4mvO

#VenoOcclusiveDisease #SinusoidalObstructionSyndrome #BMTsm

[Harry Bull @hottibull]

@AaronGoodman33 @WardiGabriel Chk for symptoms for VOD/SOS Tx=Defibrotide chk all symptoms incl painful hepatomegaly and lymphocytopenia, >2%incr weight gain. temp=poss cytokine storm

[AML Hub @AML_Hub]

CONGRESS | #EBMT21 | Sergey Bondarenko, Pavlov University, presents the data of a study evaluating gilteritinib for the treatment of R/R AML and highlights the promising efficacy and toxicity profiles of the agent in adult patients both prior to and following allo-HSCT. #leusm

[Chris Hourigan @DrChrisHourigan]

My thoughts on "A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients" | Blood Advances | American Society of Hematology https://t.co/6hL0WBpqJm

[Harry Bull @hottibull]

Defibrotide for the treatment of severe VOD/SOS in adults regardless of time of onset. Early and Late Onset Veno‐Occlusive Disease/Sinusoidal Syndrome Post Allogeneic Stem Cell Transplantation – A Real World UK Experience https://t.co/WNjeFZeR9x

[Aaron Logan, MD, PhD, MPhil @hemedoc]

@AaronGoodman33 False scenario in a way. MRD is always measurable. If referred a pt in CR who doesn’t have an MRD assessment, it’s easy to aspirate a marrow sample specifically to send for MRD quant. No reason to send for “everything” with the associated costs of everything. #mrdmatters

[Naveen Pemmaraju, MD @doctorpemm]

👉👉👉Our group’s new paper led by ⁦@musayilmaz54⁩ & Dr Daver ➡️ Outcomes w/sequential #FLT3-inhibitor-based therapies in patients w/AML | ⁦@Malfayez7⁩ ⁦⁩ ⁦@TapKadia⁩ @sanamloghavi⁩ ⁦@kanagalshamanna⁩ #leusm #endcancer https://t.co/GHcy4robwn

[Roland B. Walter, MD PhD MS @RolandBWalter]

How to monitor MRD in AML? BM or PB? Our most recent multi-parameter flow cytometric analysis in PB/BM pairs from 209 AML patients with MRD-level disease, showing PB testing captures 83% of patients with MRD in BM with excellent specificity (95%). https://t.co/YFarn7u1Ws

[AML Hub @AML_Hub]

Congress| #IACH2020| Richard Stone, @DanaFarber gave a closing lecture about FLT3 inhibitors in #AML. #leusm

[Chris Hourigan @DrChrisHourigan]

Post doc positions available in https://t.co/g12S3sSC1Q through this excellent @TheBethesdaLabs program - come work on precision medicine for a rare high-risk blood cancer (AML MRD) using cutting edge genomic including single-cell approaches. #leusm #postdoc

[Harry Bull @hottibull]

Chemo related toxicity -> Acute liver dysfunction >20% mortality
#hsct #bmt #vodsos #sepsis #earlyDiagnosis #bilirubin #hepatomegaly #ALT #AST https://t.co/zlVMXInLk4

[Harry Bull @hottibull]

Heparinoid Rx in disseminated intravascular coagulation. #HSCT #VODSOS #AML #leusym ⁦@KNOW_AML⁩ ⁦@ASCO⁩
https://t.co/rhmECaOqDY

[AML Hub @AML_Hub]

Why should we use MRD assessment post hematopoietic stem cell transplantation? Prof. Craddock will discuss this during the virtual #AML Hub Satellite Symposium at #EBMT20Virtual. LEAD THE CONVERSATION & submit your questions for Prof. Craddock here https://t.co/8wD5Wugapp #leusm

[Chris Hourigan @DrChrisHourigan]

@AML_Hub @nih_nhlbi The plenary at EHA the year after (EHA24) is more relevant :-) https://t.co/IGRMOmvikS

[Harry Bull @hottibull]

Potential targeting of #FLT3 #AML #leusym
- improves rates of first remission & transplant by reducing/
eliminating FLT3 MRD.

Can someone pls explain the continued practice of referencing "minimal" cf measurable residual disease (MRD)?

https://t.co/F8XCF5n8Ve

[Harry Bull @hottibull]

Donor-derived T-cell activation & inflammatory cytokine bursts can trigger vascular endothelial injury
PS, HLA mismatch & aGVHD, Aspergillus infection, & VOD/SOS = risk factors for TA-TMA.

#HSCT #VODSOS #leusm #hematology #leukemia #BMT #aHSCT #MAC

via https://t.co/o9OeEKo7Dt

[Saudi Leukemia Net @SaudiLeukemia]

Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN) | Journal of Clinical Oncology https://t.co/3AlF1yuaRj

[Harry Bull @hottibull]

https://t.co/nyEdxgfkJK

CY-BU less toxic condtioning Rx in #hsct

Liver toxicity & VOD/SOS is a life- threatening complication after myeloablative #hsct w mean values of AST and ALT significantly higher in BU-CY gp (n=28) to CY-BU gp (n=27) (p<0.05)

[Harry Bull @hottibull]

#Defibrotide - Prophylaxis to protect chemo-induced #endothelial damage in humans (ref #VOD_SOS) and prophylaxis for #aGvHD in mice @justsaysinmice #HSCT #AML #AlloHSCT The catch? Defibrotide is prohibitively $$$$$ @JazzPharma

https://t.co/ZievRxG3Rw

[Ibrahim Yakoub-Agha @i_yakoub_agha]

Cytogenetic Risk Score Maintains Its Prognostic Significance in AML Patients With Detectable Measurable Residual Disease Undergoing Transplantation in Remission: On Behalf of the ALWP/EBMT - PubMed ⁦@TheEBMT⁩ ⁦@JACIE_EBMT⁩ ⁦@SFGM_TC⁩ https://t.co/xdQ8zStw27

[Harry Bull @hottibull]

Endothelial syndrome vs VOD/SOS.

More work to understand, assess, & treat post-allo #HSCT related endothelial damage

Need comprehensive classificatn & frontline & prophylactic strategies

https://t.co/RAr8KS4mvO

#VenoOcclusiveDisease #SinusoidalObstructionSyndrome #BMTsm